introduction to imi...medicines safety – the challenge a major challenge in drug development is...
TRANSCRIPT
What is the Innovative Medicines Initiative?
> €5 bn
Partnership
2008 - 2024
€2.5 bn
€2.5 bn
EU funding goes to:
- universities
- SMEs
- patient groups
etc…
EFPIA companies
- receive no funding
- contribute to
projects ‘in kind’
Europe’s partnership for health
Why do we need IMI?
risky inefficient
expensive
complex
time
consuming
Because drug development is very…
Because…
Not enough
science
throughout
development
Clinical trial
designs not
always optimal Regulatory
pathways not
always optimised
All of this has a significant impact on the affordability and speed of access
for innovation for patients
How is IMI addressing the challenges in drug development?
Through IMI’s projects we are trying to…
put patients at the centre
share risk (among public & private players)
increase efficiency (by developing common tools)
reduce duplication of effort (esp. at early stages)
reduce timelines (by using a personalised medicine approach)
integrate the latest science into drug development
use data and knowledge management to work more effectively
We do this by creating a neutral platform where all involved in
drug development – academics, industry, SMEs, patients, regulators,
others – can engage in open collaboration on shared challenges.
What is IMI delivering?
2 272 FTE jobs
directly associated
with IMI projects
20 patent
applications
169 SMEs
13 spin-offs
25+ new tools
to facilitate drug
development 1 600+ scientific
publications
65 clinical studies
460+ biological marker
candidates for better
diagnosis & treatment
Medicines safety – the challenge
A major challenge in drug development is finding medicines that
treat the disease but are not toxic to vital organs like the heart,
liver, kidneys, etc…
Too often, toxicity issues are only picked up late in drug
development, when vast amounts of time and money have been
spent on a drug.
IMI projects are developing simple tests to detect
toxicity issues earlier in drug development.
Medicines safety – an IMI success
What eTOX did
Pharma data
+
Public data
=
One big database
underlying multiple
computer-based tools
Example: Will this be toxic to the heart?
Output =
possible effect
on heart – ECG
result!
Input = 2D
structure of a
possible drug
Project partners
using tools
Reducing animal
testing
Medicines development – the challenge
We don’t know enough about the underlying causes of many
diseases – we need this information to develop effective
treatments!
We don’t have the tools to study the underlying causes of many
diseases
IMI projects are developing tools and
establishing networks to study diseases and
making new discoveries on the underlying
causes of diseases.
Medicines development – an IMI success
Autism…
affects 1 in 110
results in difficulties in
social interaction &
communication,
repetitive behaviours
has a major impact on
families & carers
has no treatments
Our EU-AIMS project has
discovered…
new insights into underlying causes
(genes etc.)
that the brain changes associated with
autism could be reversed
gender differences in the brains of
men and women with autism
Patients involved
Working with
regulators
Recognised globally
as flagship project
Through its European Lead Factory project, IMI
has created a state-of-the-art compound
collection & screening centre that is delivering
results for academics, SMEs & pharma
Medicines development – the challenge
High Throughput Screening (HTS) = researchers screen large
collections of chemical compounds in hunt for molecules that could
be potential drugs or be used in drug development in other ways.
Pharmaceutical companies have huge compound collections,
but access to these is usually tightly restricted…
Public compound collections exist, but are small and expertise
is scattered across many institutions.
Medicines development – an IMI success
Joint European
Compound
Collection
European
Screening Centre
320 000 cpds
from 7 pharma
companies
200 000 cpds
from public
partners
Advanced, ultra
high throughput
screening
facilities &
expertise on
logistics, medicinal
chemistry, etc.
‘Access to the European Lead Factory has
fast-forwarded our drug discovery
programme in the field of oncology by
several years.’ – Huib Ovaa, Netherlands
Cancer Institute
‘ELF support & its high quality compound
library … will allow Effecta Pharma to
expand its drug discovery efforts for
dengue and gives an important boost to
tackling this viral disease.’ – Effecta
Pharma, UK biotech company
Leading role for SMEs
Quality & diversity of compounds recognised
Award-winning IP solution
Happy users!
Stay in touch
Visit our website
www.imi.europa.eu
Sign up to our newsletter
bit.ly/IMInewsletter
Follow us on Twitter
@IMI_JU
Join our LinkedIn group
bit.ly/LinkedInIMI
E-mail us